CONFIDENTIAL — APPROVED FOR PUBLIC RELEASE · BUREAU FILE COPY RECORDS CURRENT AS OF 29 MAY 2026 · DISTRIBUTION: UNRESTRICTED
VendorInvestigator Independent Testing Bureau · Public Records Division
DOCKET YEAR 2026 · VOL. II
35,156 SAMPLES ON FILE
No fee · No favor
Compound Evidence File
#EC-2026-0366

1-Benzyl-4-piperidone CAS 3612-20-2

Filed under Raw Materials. The bureau holds 100 laboratory returns for this compound from 32 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.

Cross-Index

Subjects Shipping This Compound

32 SUBJECTS
SubjectGradeSamplesMeanMinMaxFirst seenLast seen
HomopeptideCASE #VI-2026-0760 A 5 10.0 9.9 10.0 24 May 2026 24 May 2026
QYAOBIOCASE #VI-2026-0861 A 4 10.0 10.0 10.0 26 Jan 2026 9 Jun 2026
JEEP PeptidesCASE #VI-2026-0457 A 4 10.0 10.0 10.0 16 Feb 2026 3 Jun 2026
Hubei JianxiangCASE #VI-2026-0048 A 4 10.0 9.9 10.0 1 Jan 2026 12 Jul 2026
WuXi TIDESCASE #VI-2026-0335 A 4 10.0 9.9 10.0 22 Jan 2026 12 May 2026
PolyPeptide GroupCASE #VI-2026-0143 A 4 10.0 9.9 10.0 12 Feb 2026 21 May 2026
BachemCASE #VI-2026-0314 A 3 10.0 10.0 10.0 1 May 2026 5 Jul 2026
Shanghai Wibson BiotechnologyCASE #VI-2026-0379 A 3 10.0 9.9 10.0 23 Feb 2026 4 Jun 2026
Shanghai Sigma AudleyCASE #VI-2026-0505 A 3 10.0 9.9 10.0 4 Jan 2026 19 May 2026
GenScript PeptidesCASE #VI-2026-0860 A 3 10.0 9.9 10.0 27 Jun 2026 11 Jul 2026
Thermo Fisher ScientificCASE #VI-2026-0142 A 3 10.0 9.9 10.0 26 May 2026 6 Jul 2026
SinoPepCASE #VI-2026-0387 A 3 10.0 10.0 10.0 1 Mar 2026 6 Jul 2026
AsymchemCASE #VI-2026-0091 A 3 10.0 9.9 10.0 7 Apr 2026 19 Jul 2026
AmbioPharmCASE #VI-2026-0177 A 3 10.0 9.9 10.0 7 Jul 2026 21 Jul 2026
Mokemei BiotechnologyCASE #VI-2026-0540 A 2 10.0 10.0 10.0 8 Dec 2025 1 Mar 2026
Flourishglobal PeptideCASE #VI-2026-0630 A 2 10.0 10.0 10.0 16 Mar 2026 9 Jun 2026
Shanghai JinBei Chemical TechnologyCASE #VI-2026-0107 X 1 10.0 10.0 10.0 21 May 2025 21 May 2025
Tianjin Finder Chemical TFCCASE #VI-2026-0693 A 5 9.9 9.9 10.0 14 Nov 2025 16 Apr 2026
Shanghai ERP BiotechnologyCASE #VI-2026-0936 A 4 9.9 9.9 10.0 3 Nov 2025 2 Jul 2026
Kerui PeptidesCASE #VI-2026-0626 A 4 9.9 9.9 10.0 11 Nov 2025 13 Jun 2026
Sangon BioCASE #VI-2026-0671 A 3 9.9 9.9 10.0 5 Jun 2026 19 Jun 2026
Chinese Peptide CompanyCASE #VI-2026-0184 A 2 9.9 9.9 10.0 15 Jun 2026 17 Jun 2026
Hybio PharmaceuticalCASE #VI-2026-0065 A 2 9.9 9.9 10.0 5 May 2026 21 Jun 2026
Sigma-AldrichCASE #VI-2026-0829 A 2 9.9 9.9 9.9 3 Feb 2026 26 Jun 2026
Qingdao Sigma Chemical QSCCASE #VI-2026-0538 A 2 8.9 8.1 9.7 23 May 2026 23 May 2026
Shanghai Sigma Audley SSACASE #VI-2026-0486 A 2 8.6 8.0 9.2 24 May 2026 24 May 2026
Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 A 3 8.5 8.1 9.0 23 May 2026 23 May 2026
Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 A 6 8.2 6.0 9.9 23 May 2026 23 May 2026
Glbiochem (Shanghai)CASE #VI-2026-0704 A 6 8.0 6.7 9.2 23 May 2026 23 May 2026
Hebei Rimao TechnologyCASE #VI-2026-0529 X 3 7.4 6.8 8.3 13 Feb 2025 24 May 2026
Nanjing Xiyuxun Technology XYXCASE #VI-2026-0433 X 1 6.2 6.2 6.2 28 Mar 2025 28 Mar 2025
Huayi BiotechnologyCASE #VI-2026-0243 X 1 4.3 4.3 4.3 2 Apr 2025 2 Apr 2025

Open any subject to view the batch-level evidence for 1-Benzyl-4-piperidone CAS 3612-20-2 alone.